For example, in a preclinical study, exosome-based nanoparticles could enhance the efficacy of delivering YY1 inhibitors into glioblastoma cells in both in vitro and in vivo models of the blood–brain barrier (BBB) [273]. Here, YY1 is linked to glioblastoma.